JP2019526589A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526589A5
JP2019526589A5 JP2019512639A JP2019512639A JP2019526589A5 JP 2019526589 A5 JP2019526589 A5 JP 2019526589A5 JP 2019512639 A JP2019512639 A JP 2019512639A JP 2019512639 A JP2019512639 A JP 2019512639A JP 2019526589 A5 JP2019526589 A5 JP 2019526589A5
Authority
JP
Japan
Prior art keywords
acid
small molecule
disease
loxl2 inhibitor
inhibitor according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512639A
Other languages
English (en)
Japanese (ja)
Other versions
JP7097874B2 (ja
JP2019526589A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/050331 external-priority patent/WO2018048942A1/en
Publication of JP2019526589A publication Critical patent/JP2019526589A/ja
Publication of JP2019526589A5 publication Critical patent/JP2019526589A5/ja
Application granted granted Critical
Publication of JP7097874B2 publication Critical patent/JP7097874B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512639A 2016-09-07 2017-09-06 リシルオキシダーゼ様2阻害剤の使用 Expired - Fee Related JP7097874B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662384542P 2016-09-07 2016-09-07
US62/384,542 2016-09-07
US201762509460P 2017-05-22 2017-05-22
US62/509,460 2017-05-22
PCT/US2017/050331 WO2018048942A1 (en) 2016-09-07 2017-09-06 Uses of a lysyl oxidase-like 2 inhibitor

Publications (3)

Publication Number Publication Date
JP2019526589A JP2019526589A (ja) 2019-09-19
JP2019526589A5 true JP2019526589A5 (enExample) 2020-10-15
JP7097874B2 JP7097874B2 (ja) 2022-07-08

Family

ID=61561650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512639A Expired - Fee Related JP7097874B2 (ja) 2016-09-07 2017-09-06 リシルオキシダーゼ様2阻害剤の使用

Country Status (13)

Country Link
US (3) US11793797B2 (enExample)
EP (3) EP3509594B1 (enExample)
JP (1) JP7097874B2 (enExample)
KR (2) KR102615565B1 (enExample)
CN (2) CN117180280A (enExample)
AU (1) AU2017324444A1 (enExample)
BR (1) BR112019004513A2 (enExample)
CA (1) CA3036062A1 (enExample)
ES (1) ES3015717T3 (enExample)
IL (1) IL265232A (enExample)
MA (1) MA46203A (enExample)
MX (1) MX2019002612A (enExample)
WO (1) WO2018048942A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144702A1 (en) * 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
WO2016144703A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
CN108884049A (zh) 2016-02-09 2018-11-23 法玛克亚公司 喹啉酮赖氨酰氧化酶样2抑制剂及其用途
MX390964B (es) 2016-09-07 2025-03-21 Pharmakea Inc Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.
MX2019002612A (es) 2016-09-07 2019-08-21 Pharmakea Inc Usos de un inhibidor de lisil-oxidasa tipo 2.
US20210002641A1 (en) * 2018-03-16 2021-01-07 The Regents Of The University Of Michigan Compositions and methods for treating graves disease
CN112441916A (zh) * 2019-08-29 2021-03-05 广东药科大学 新型苯乙酸衍生物、其制备方法及其作为药物的用途
JP2022548725A (ja) * 2019-09-20 2022-11-21 レネオ ファーマシューティカルズ,インク. 腎臓病の治療におけるpparデルタアゴニストの使用
WO2021086973A2 (en) * 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation for delivery of lubricin gene
CN110714016B (zh) * 2019-11-29 2021-08-20 长沙学院 Jnk基因及其作为鱼类细菌性肠炎诊断分子标记物和治疗靶点的应用
CN112662763A (zh) * 2020-03-10 2021-04-16 博尔诚(北京)科技有限公司 一种检测常见两性癌症的探针组合物
CN116600802A (zh) * 2020-12-03 2023-08-15 德尔塔4有限公司 沙罗格列扎和肉豆蔻酸用于治疗局灶性节段性肾小球硬化(fsgs)
CN117731665B (zh) * 2021-07-12 2026-03-27 兰州大学 喹吖因或其药学上可接受的盐在制备治疗非酒精性脂肪肝药物中的应用
US20250249013A1 (en) * 2022-04-08 2025-08-07 The Regents Of The University Of California Combination metabolic-epigenetic treatment for early lung cancer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
IE56702B1 (en) 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5250532A (en) 1991-04-11 1993-10-05 Dowelanco 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
MXPA02007047A (es) 2000-01-18 2002-12-13 Pfizer Prod Inc Antagonista del factor liberador de corticotropina.
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
FI20030030A0 (fi) 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
CN1787817B (zh) 2003-05-19 2011-09-07 Irm责任有限公司 免疫抑制剂化合物及组合物
WO2005082370A1 (en) 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
CA2558568A1 (en) 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
WO2005092836A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
CN1976907A (zh) 2004-04-30 2007-06-06 武田药品工业株式会社 杂环酰胺化合物及其作为mmp-13抑制剂的用途
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
BRPI0515143A (pt) 2004-09-10 2008-07-08 Pfizer Prod Inc usos de derivados azabicìclicos de piridiloximetila e benzisoxazol para a preparação de uma composição farmacêutica para o tratamento dos distúrbios de humor
JP2008512441A (ja) 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法
WO2006052546A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
DE102004056226A1 (de) 2004-11-22 2006-05-24 Burchardt, Elmar Reinhold, Dr.Dr. Neuartige Inhibitoren der Lysyloxidase
US7759493B2 (en) 2005-01-31 2010-07-20 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
AR055041A1 (es) 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
CA2618586A1 (en) 2005-08-11 2007-02-15 Merck Frosst Canada Ltd. Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
ITMI20051943A1 (it) 2005-10-14 2007-04-15 Procos Spa Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2007087250A2 (en) 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
EP2121703A4 (en) 2006-08-18 2011-12-28 Astrazeneca Ab THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS
US20100074897A1 (en) * 2006-12-01 2010-03-25 University Of Utah Research Foundation Methods and Compositions related to HIF-1 alpha
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
KR20130031233A (ko) 2009-07-28 2013-03-28 아나코르 파마슈티칼스 인코포레이티드 삼치환된 붕소 함유 분자
EP2467162A4 (en) * 2009-08-21 2013-10-02 Gilead Biologics Inc THERAPEUTIC PROCESSES AND RELATED COMPOSITIONS
US8680246B2 (en) * 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
JP2013518909A (ja) 2010-02-08 2013-05-23 キナゲン,インク. アロステリックキナーゼ阻害が関係する治療方法および組成物
US8513230B2 (en) 2010-03-05 2013-08-20 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
BR112014026399B1 (pt) 2012-04-25 2022-11-01 Raqualia Pharma Inc Composto de fórmula (ii), composição farmacêutica, uso e processo para preparar uma composição farmacêutica
JP2016500700A (ja) * 2012-10-30 2016-01-14 ギリアード サイエンシーズ, インコーポレイテッド リシルオキシダーゼ様2(loxl2)に関する治療および診断方法
CN104854086B (zh) 2012-12-18 2017-06-27 Ea制药株式会社 杂环酰胺衍生物和含有其的药物
JP2018522812A (ja) 2014-08-05 2018-08-16 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア カスパーゼ−6のモジュレーター
US9051320B1 (en) * 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
WO2016128529A1 (en) 2015-02-15 2016-08-18 F. Hoffmann-La Roche Ag 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists
WO2016144703A1 (en) * 2015-03-06 2016-09-15 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
WO2016144702A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
MX390964B (es) 2016-09-07 2025-03-21 Pharmakea Inc Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.
MX2019002612A (es) 2016-09-07 2019-08-21 Pharmakea Inc Usos de un inhibidor de lisil-oxidasa tipo 2.

Similar Documents

Publication Publication Date Title
ES2384110T3 (es) Anticuerpo anti-PLGF novedoso
JP2015521167A5 (enExample)
ES2392030T3 (es) Tratamiento de transtornos neovasculares oculares, tales como degeneración macular, estrías angioides, uveítis y edema macular
JP2016519680A5 (enExample)
ES2892954T3 (es) Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos
KR101088942B1 (ko) Ep2 작용제
JP2021508686A5 (enExample)
CN105980365B (zh) 作为mIDH1抑制剂的苯并咪唑-2-胺
JP2019524710A5 (enExample)
CN113891745A (zh) 作为p2x3抑制剂的氨基喹唑啉衍生物
JP2020530470A5 (enExample)
JP2022534751A5 (enExample)
JP7683930B2 (ja) セミカルバジド感受性アミンオキシダーゼ阻害剤の調製及びその応用
JP6204921B2 (ja) シクロスポリンaの形態2およびその作製方法
ES2704641T3 (es) Compuestos N-hidroxiamidinoheterocíclicos como moduladores de la indoleamina 2,3-dioxigenasa
JP2016540017A5 (enExample)
TW201113288A (en) Inhibitors of protein tyrosine kinase activity
JP2019501910A5 (enExample)
JP6738512B2 (ja) 眼血管形成(ocular neovasculan)を治療するのに有用な化合物
CN115485027A (zh) 冠状病毒感染引起的化学感觉功能障碍的治疗
CN107074773A (zh) 取代的n,2‑二芳基喹啉‑4‑甲酰胺及其用途
JP2018505163A5 (enExample)
JP2024525368A5 (enExample)
JP2019525915A5 (enExample)
JP2022106998A (ja) 眼圧下降増強剤